These findings show that the abundance of tumor-reactive CD8+ T cells versus the immunosuppressive Treg cells characterized the rapid model of MM progression driven by MYC activation, which may have favored the activity of anti-PD-1 therapy. The gene discussed is CD8A; the disease is Miyoshi myopathy.